Structures by: Suresh K.
Total: 39
C16H16ClN5O6S
C16H16ClN5O6S
Journal of Pharmaceutical Sciences (2012) 101, 664-680
a=7.909(4)Å b=9.467(5)Å c=12.484(7)Å
α=100.151(8)° β=95.950(8)° γ=97.644(9)°
C20H18ClN6O7S
C20H18ClN6O7S
Journal of Pharmaceutical Sciences (2012) 101, 664-680
a=7.512(2)Å b=9.462(3)Å c=17.198(5)Å
α=95.387(5)° β=102.271(5)° γ=110.101(5)°
Sparfloxacin-methyl paraben cocrystal
C19H22F2N4O3,C8H8O3
Chemical communications (Cambridge, England) (2016) 52, 85 12610-12613
a=9.423(5)Å b=12.742(7)Å c=12.890(7)Å
α=62.717(9)° β=70.160(9)° γ=76.407(10)°
Sparfloxacin-Propylparaben cocrystal
C19H22F2N4O3,C10H10O3
Chemical communications (Cambridge, England) (2016) 52, 85 12610-12613
a=7.9588(4)Å b=10.3333(5)Å c=17.8484(9)Å
α=80.749(4)° β=87.489(4)° γ=72.019(5)°
Sparfloxacin-ethyl paraben cocrystal
C19H22F2N4O3,C9H8O3
Chemical communications (Cambridge, England) (2016) 52, 85 12610-12613
a=9.5457(5)Å b=12.8769(6)Å c=13.3380(7)Å
α=62.8916(14)° β=71.3599(16)° γ=77.1301(16)°
Sparfloxacin-Isobutylparaben corystal
C19H22F2N4O3,C11H14O3
Chemical communications (Cambridge, England) (2016) 52, 85 12610-12613
a=9.5693(7)Å b=9.7134(7)Å c=17.7964(12)Å
α=74.767(3)° β=76.025(3)° γ=69.597(3)°
Indapamide-4,4'-Bipyridine cocrystal
C16H16ClN3O3S,C10H8N2
CrystEngComm (2019) 21, 13 2043
a=7.2851(14)Å b=9.0281(17)Å c=38.510(7)Å
α=90° β=95.230(3)° γ=90°
Indapamide-methylpyridone cocrystal
C16H16ClN3O3S,C6H7NO
CrystEngComm (2019) 21, 13 2043
a=7.765(7)Å b=8.741(8)Å c=34.52(3)Å
α=90° β=93.96(4)° γ=90°
Indapamide-2,2'-Bipyridine cocrystal
C16H16ClN3O3S,C10H8N2
CrystEngComm (2019) 21, 13 2043
a=7.3151(2)Å b=8.9370(3)Å c=38.9526(12)Å
α=90° β=93.702(2)° γ=90°
Indapamide-Phenazine cocrystal
C16H16ClN3O3S,C12H8N2
CrystEngComm (2019) 21, 13 2043
a=7.1759(3)Å b=9.4074(4)Å c=39.0523(17)Å
α=90° β=93.389(2)° γ=90°
Indapamide-1,2-Bis(4-pyridyl)ethylene cocrystal monohydrate
C16H16ClN3O3S,C12H10N2,H2O
CrystEngComm (2019) 21, 13 2043
a=12.2238(2)Å b=14.8267(3)Å c=16.2328(3)Å
α=93.2280(10)° β=107.2640(10)° γ=90.1220(10)°
Epalrestat
C15H13NO3S2
Chemical communications (Cambridge, England) (2016) 52, 21 4037-4040
a=13.7384(4)Å b=9.1063(3)Å c=24.1429(7)Å
α=90° β=100.747(3)° γ=90°
Epalrestat
C15H13NO3S2
Chemical communications (Cambridge, England) (2016) 52, 21 4037-4040
a=8.1399(10)Å b=11.5584(14)Å c=16.1506(19)Å
α=96.721(10)° β=93.818(10)° γ=104.724(10)°
Epalrestat
C15H13NO3S2
Chemical communications (Cambridge, England) (2016) 52, 21 4037-4040
a=11.4252(5)Å b=6.9479(3)Å c=19.4673(9)Å
α=90° β=102.898(5)° γ=90°
Epalrestat
C15H13NO3S2
Chemical communications (Cambridge, England) (2016) 52, 21 4037-4040
a=14.7831(13)Å b=5.6288(5)Å c=18.2621(16)Å
α=90° β=98.364(8)° γ=90°
Glibenclamide
C23H28ClN3O5S
CrystEngComm (2017) 19, 6 918
a=9.45444(13)Å b=17.6795(3)Å c=14.4839(2)Å
α=90° β=93.4373(13)° γ=90°
Glibenclamide-sodiumhydrate salt
C23H27ClN3NaO6S
CrystEngComm (2017) 19, 6 918
a=19.5991(16)Å b=5.8086(3)Å c=23.4722(17)Å
α=90° β=108.746(8)° γ=90°
Glibenclamidesodium salt
C23H27ClN3NaO5S
CrystEngComm (2017) 19, 6 918
a=10.9425(10)Å b=10.1583(7)Å c=11.5023(11)Å
α=90° β=91.164(9)° γ=90°
Glibenclamide-ammonium salt
C23H31ClN4O5S
CrystEngComm (2017) 19, 6 918
a=19.718(4)Å b=6.1475(11)Å c=21.732(5)Å
α=90° β=109.25(2)° γ=90°
Glibenclamide-potassium salt
C23H27ClKN3O5S
CrystEngComm (2017) 19, 6 918
a=19.819(4)Å b=6.2006(9)Å c=21.636(5)Å
α=90° β=109.69(2)° γ=90°
Glibenclamidesodium salt
C23H27ClN3NaO5S
CrystEngComm (2017) 19, 6 918
a=19.7594(13)Å b=6.1759(3)Å c=21.5560(15)Å
α=90° β=109.627(7)° γ=90°
Naproxen--picolinamide (1/1)
C14H14O3,C6H6N2O1
Acta Crystallographica Section C (2017) 73, 3 168-175
a=5.3048(5)Å b=31.891(3)Å c=10.5080(10)Å
α=90° β=98.184(3)° γ=90°
Aceclofenac-piperazine(0.5)-hydrate
C18H20Cl2N2O5
Crystal Growth & Design (2013) 13, 4 1590
a=14.555(4)Å b=14.950(4)Å c=8.557(3)Å
α=90.00° β=92.473(4)° γ=90.00°
Lornoxicam Mesylate salt
C14H14N3O7S3Cl
Crystal Growth & Design (2014) 14, 6 2945
a=13.4730(11)Å b=13.2684(8)Å c=11.2407(8)Å
α=90.00° β=111.707(9)° γ=90.00°
Lornoxicam Piperazine salt
C15H16N4O4S2Cl
Crystal Growth & Design (2014) 14, 6 2945
a=13.2445(9)Å b=13.0698(7)Å c=11.6414(8)Å
α=90.00° β=111.547(8)° γ=90.00°
Lornoxicam
C13H10N3O4S2Cl
Crystal Growth & Design (2014) 14, 6 2945
a=7.2020(4)Å b=13.5420(8)Å c=14.9987(7)Å
α=90.00° β=90.00° γ=90.00°
Lornoxicam Hydrochloride salt
C13H11N3O4S2Cl2
Crystal Growth & Design (2014) 14, 6 2945
a=6.8795(5)Å b=9.1606(8)Å c=26.201(2)Å
α=90.00° β=90.00° γ=90.00°
Sulfamethizole-4-aminobenzamide cocrystal
C9H10N4O2S2,C7H8N2O
Crystal Growth & Design (2015) 15, 7 3498
a=13.5102(6)Å b=15.2418(6)Å c=18.3238(7)Å
α=99.534(3)° β=98.720(3)° γ=90.086(3)°
Sulfamethizole-subericacid cocrystal
2(C9H10N4O2S2),C8H14O4
Crystal Growth & Design (2015) 15, 7 3498
a=10.4481(3)Å b=19.2259(5)Å c=16.5666(7)Å
α=90.00° β=90.00° γ=90.00°
Sulfamethizole-bipyridine cocrystal
C9H10N4O2S2,C10H8N2
Crystal Growth & Design (2015) 15, 7 3498
a=8.1754(7)Å b=18.6120(10)Å c=13.1690(11)Å
α=90.00° β=93.048(7)° γ=90.00°
Sulfamethizole-adipic acid cocrystal
C9H10N4O2S2,0.5(C6H10O4)
Crystal Growth & Design (2015) 15, 7 3498
a=7.9915(4)Å b=21.6918(8)Å c=8.5756(4)Å
α=90.00° β=95.737(4)° γ=90.00°
Sulfamethizole-4-aminobenzoicacid cocrystal
C9H10N4O2S2,C7H7NO2
Crystal Growth & Design (2015) 15, 7 3498
a=9.2097(3)Å b=10.8241(5)Å c=18.2910(7)Å
α=90.00° β=101.645(3)° γ=90.00°
Sulfamethizole-vanillic acid cocrystal
C9H10N4O2S2,C8H8O4
Crystal Growth & Design (2015) 15, 7 3498
a=8.1263(5)Å b=19.7763(7)Å c=12.0584(7)Å
α=90.00° β=109.396(4)° γ=90.00°
Sulfamethizole-mono-oxalate salt
C9H11N4O2S2,C2HO4
Crystal Growth & Design (2015) 15, 7 3498
a=8.0559(3)Å b=20.6543(6)Å c=8.5539(4)Å
α=90.00° β=99.903(3)° γ=90.00°
2-(2,6-dichlorophenylamine)phenylacetoxyacetic acid
C16H13Cl2NO4
Crystal Growth & Design (2013) 13, 4 1590
a=12.284(3)Å b=8.198(2)Å c=15.484(4)Å
α=90.00° β=96.174(4)° γ=90.00°
Aceclofenac-cytosine
C20H18Cl2N4O5
Crystal Growth & Design (2013) 13, 4 1590
a=11.2960(10)Å b=8.7429(8)Å c=20.8507(19)Å
α=90.00° β=98.0120(10)° γ=90.00°
Aceclofenac-piperazine(0.5)
C18H18Cl2N2O4
Crystal Growth & Design (2013) 13, 4 1590
a=9.1898(11)Å b=5.5983(7)Å c=34.890(4)Å
α=90.00° β=94.038(2)° γ=90.00°
C42H36Cl4N4O9
C42H36Cl4N4O9
Crystal Growth & Design (2013) 13, 4 1590
a=7.5085(5)Å b=11.9908(8)Å c=22.2488(15)Å
α=90.00° β=91.5690(10)° γ=90.00°
Lornoxicam Ammonium salt
C13H13N4O4S2Cl
Crystal Growth & Design (2014) 14, 6 2945
a=7.5577(7)Å b=10.3747(9)Å c=12.0879(12)Å
α=68.516(9)° β=75.433(8)° γ=70.585(8)°